SecBot SecBot

ANAB

ANAPTYSBIO, INC
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001370053 Biotech & Drug Discovery
$45.73 −0.52 (−1.12%)
Nov 16 4:00 PM ET · prev $46.25
Market cap
$1.4B
Small cap
Consensus
Buy
93% Buy or better · 15 analysts
Median target
$79.50
+74% · range $60.00–140.00
1 year
+97.3%
from $23.18 · Nov 17
30 days
−7.1%
from $49.24
52-week range
$23.18–69.81
−34% from high · low Nov 17
Avg volume 20D
410.3K
Oct 20 spike 1.21M
Short interest
5.05M
≈17.1% of shares · −6.3%
Days to cover
10.8
at average volume
Insider net
−$249.4K
0 buyers · 1 seller · since Apr 20
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
25
analyzed by SecBot
SecBot read BEARISH 4 reports · 90 days
Balance 1 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 1/4 ·Next FDA decision date, Dec 12, 2026

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $249.4K.

  • InstitutionsBULLISH

    Q3 2026: 26 added (0 new), 15 trimmed or exited.

  • AnalystsBULLISH

    14 of 15 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate $0.730 → $1.055 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest −6.3% to 5.05M shares. 10.8 days to cover, ≈17.1% of shares.

  • TrendRANGE

    8% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
MORGAN STANLEYADD404,164$20.3M
VANGUARD PORTFOLIO MANAGEMENT LLCTRIM371,647$18.7M
Squarepoint Ops LLCTRIM109,720$5.5M
Connor, Clark & Lunn Investment Management Ltd.TRIM94,037$4.7M
CAPITAL FUND MANAGEMENT S.A.DOUBLED85,871$4.3M
Russell Investments Group, Ltd.DOUBLED84,859$4.3M
DEUTSCHE BANK AG\ADD70,386$3.5M
FRANKLIN TEMPLETON INCTRIM73,745$3.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 93% rate it Buy or better
Strong Buy5Buy9Hold1Sell0Strong Sell0
12-month targets · 8 analysts

Price is below the lowest target. Median implies +74%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Sep 30, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Sep 24, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 23, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
Aug 25, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Aug 24, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$249.4K
sold · 1 insider
DateInsiderTypeValue
Oct 1, 2026
RENTON HOLLINGS
Director
Oct 1, 2026
SELL$249.4K
Oct 1, 2026
RENTON HOLLINGS
Director
Oct 1, 2026
EXERCISE$90.2K
Sep 15, 2026
Orwin John A
Director
Sep 15, 2026
EXERCISE1,300 sh
Jun 15, 2026
Orwin John A
Director
Jun 15, 2026
EXERCISE6,030 sh
Jun 15, 2026
RENTON HOLLINGS
Director
Jun 15, 2026
EXERCISE6,030 sh
Jun 15, 2026
Schmid John P.
Director
Jun 15, 2026
EXERCISE6,030 sh
May 11, 2026
Hughes Owen
Director
May 11, 2026
AWARD11,250 sh
May 11, 2026
Murphy Christopher M.
Chief Financial Officer
May 11, 2026
AWARD25,765 sh

Earnings setup

Estimates
$1.05
EPS estimate, this quarter
+45%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$1.05$0.10–$2.01-31.7%$52.6M
Next Q🔒 Fresh data, subscribers only
Current FY$3.24$2.49–$3.74-25.5%$136.7M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
5,050,250
shares short
-6.3%
vs prior settlement
10.8
days to cover
≈17.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 12, 2026 SEC
AnaptysBio reported Q1 FY2027 (Sep 2026) collaboration revenue of $30.3M, below the $33.5M consensus, and GAAP EPS of…
PRESS-RELEASE · Impact 4/10
Nov 12, 2026 Earnings
Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on m
Nov 6, 2026 SEC
Four small asset managers added or doubled their ANAB positions in Q3 2026, with Barclays and Farther Finance making…
INST-CLUSTER · Impact 2/10
Oct 1, 2026 Insider
RENTON HOLLINGS sold 5,000 shares
Director @ $49.87 ($249.4K)
Oct 1, 2026 Insider
RENTON HOLLINGS acquired via exercise 5,000 shares
Director @ $18.03 ($90.2K)
Sep 30, 2026 Inst.
MORGAN STANLEY · ADD
404,164 shares ($20.3M)
Sep 30, 2026 Inst.
VANGUARD PORTFOLIO MANAGEMENT LLC · TRIM
371,647 shares ($18.7M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Recent
Nov 12, 2026
Earnings
Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for…
Nov 10, 2026
Press release
Anaptys Announces Participation in Upcoming Investor Conferences
SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for…
Nov 10, 2026
Earnings date
ANAB Q3 2026 Earnings After Market Close · 2026-11-10
Oct 19, 2026
Press release
Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer
Approval based on AZUR-1 data showing significant proportion of participants with no detectable signs of cancer one year or more after treatment No…
Sep 21, 2026
Earnings
Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update
SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for…

SecBot reports

25 filings · 3 press releases · 2 bullish · 15 bearish · 8 neutral
All ANAB filing & press-release reports (28)